179 related articles for article (PubMed ID: 25806320)
1. Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?
Hirsch FR
Transl Lung Cancer Res; 2014 Dec; 3(6):363-4. PubMed ID: 25806320
[No Abstract] [Full Text] [Related]
2. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
[TBL] [Abstract][Full Text] [Related]
3. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
Mountzios G
Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.
Hao Y; Xu M; Jin J; Si J; Xu C; Song Z
Cancer Med; 2023 Aug; 12(15):15903-15911. PubMed ID: 37306192
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Lee Y; Kim TM; Kim DW; Kim S; Kim M; Keam B; Ku JL; Heo DS
J Thorac Oncol; 2019 Sep; 14(9):1556-1566. PubMed ID: 31108249
[TBL] [Abstract][Full Text] [Related]
6. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation
Sullivan I; Planchard D
Front Med (Lausanne); 2016; 3():76. PubMed ID: 28149837
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
9. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated
Li T; Chang K; Qiu X; Lai Z; Luo Y; Chen J; Lv W; Lin Z; Pei X; Wu X; Wang X
Transl Lung Cancer Res; 2023 Jun; 12(6):1256-1263. PubMed ID: 37425401
[TBL] [Abstract][Full Text] [Related]
11. EGFR first- and second-generation TKIs-there is still place for them in
Karachaliou N; Fernandez-Bruno M; Bracht JWP; Rosell R
Transl Cancer Res; 2019 Jan; 8(Suppl 1):S23-S47. PubMed ID: 35117062
[TBL] [Abstract][Full Text] [Related]
12. Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors.
Lu Z; Yi Y; Wang L; Luo Y; Luo D; Xiong L; Shu Y; Luo H; Li J; Zhu W; Zeng Z; Liu A
Transl Oncol; 2024 Jan; 39():101834. PubMed ID: 38006760
[TBL] [Abstract][Full Text] [Related]
13. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
Tatineni V; O'Shea PJ; Ozair A; Khosla AA; Saxena S; Rauf Y; Jia X; Murphy ES; Chao ST; Suh JH; Peereboom DM; Ahluwalia MS
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190312
[No Abstract] [Full Text] [Related]
14. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
15. Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs.
Li D; Wang J; Liu C; Luo Y; Xu H; Wang Y; Sun N; He J
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189759
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
17. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.
Yu X; Si J; Wei J; Wang Y; Sun Y; Jin J; Zhang X; Ma T; Song Z
Cancer Med; 2023 Mar; 12(5):5630-5638. PubMed ID: 36380563
[TBL] [Abstract][Full Text] [Related]
18. Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.
Koulouris A; Tsagkaris C; Corriero AC; Metro G; Mountzios G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884398
[TBL] [Abstract][Full Text] [Related]
19. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
Wu L; Ke L; Zhang Z; Yu J; Meng X
Front Oncol; 2020; 10():602762. PubMed ID: 33392095
[TBL] [Abstract][Full Text] [Related]
20. Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors.
Sun SY
Chin Med J Pulm Crit Care Med; 2023 Mar; 1(1):3-10. PubMed ID: 37609474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
